News Releases

Juvenescence

Juvenescence Debuts New Product to Aid in Supporting a Healthy Metabolism

Juvenescence Ltd., a longevity biotech and life sciences company announced the launch of Metabolic Switch, an evidence-based, breakthrough C6 Ketone Di-ester drink that puts the consumer in ketosis to promote a healthy metabolism.

April 15, 2021

Read More
Juvenescence

Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer

Juvenescence announces that Dr. Grazia Piizzi has joined its Executive Management Team as Chief Scientific Officer.

April 6, 2021

Read More
AgeX Therapeutics

Juvenescence Partner AgeX Therapeutics Announces Preprint Article Relating to Regeneration, Aging, and Cancer

AgeX Therapeutics announced the online publication of data relating to regeneration, aging, and cancer in bioRxiv.

March 12, 2021

Read More
AgeX Therapeutics, Inc. & LyGenesis, Inc.

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.

March 2, 2021

Read More
LyGenesis

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease

LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).

December 30, 2020

Read More
AgeX Therapeutics

Juvenescence Partner AgeX Therapeutics Sublicenses Stem Cell Line for Development of Covid-19 Therapy

AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes. Scree...

October 28, 2020

Read More
Juvenescence

Juvenescence Announces Licensing Agreement with Evgen Pharma PLC

Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.

September 15, 2020

Read More
Relation Therapeutics

Relation Therapeutics Receives $1.3M Grant From the Gates Foundation to Identify Covid-19 Therapeutic Candidates

Relation Therapeutics, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.

September 1, 2020

Read More
LyGenesis

LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology

LyGenesis announces four new peer-reviewed publications highlighting its advancing technology for kidney and liver regeneration.

August 27, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics Announces Agreement with Pluristyx

AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.

June 16, 2020

Read More
Juvenomics

G3 Therapeutics and Juvenescence form Juvenomics

Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.

June 1, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics and Sernova collaborate to engineer Universal Locally Immune Protected Cell Therapies

AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.

May 29, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics licensee ImStem Biotechnology announces FDA Cleared Investigational New Drug Application

AgeX Therapeutics, a Juvenescence partner, announced that ImStem Biotechnology has received notification from the FDA that it has cleared the investigational New Drug application to evaluate IMS001 for the treatment of multiple sclerosis.

March 20, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics to collaborate with University of California, Irvine on Neural Stem Cell Research Program

AgeX, a Juvenescence partner, announced a research collaboration with the UC Irvine using AgeX’s PureStem® to derive neural stem cells with the goal of developing cellular therapies to treat neurological disorders and diseases with no cure.

February 3, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

January 29, 2020

Read More
Contact Us
We are here to help answer any questions you might have.